TY - JOUR
T1 - Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico
AU - FRIDA Study Group
AU - Rudolph, Samantha E.
AU - Lorincz, Attila
AU - Wheeler, Cosette M.
AU - Gravitt, Patti
AU - Lazcano-Ponce, Eduardo
AU - Torres-Ibarra, Leticia
AU - León-Maldonado, Leith
AU - Ramírez, Paula
AU - Rivera, Berenice
AU - Hernández, Rubí
AU - Franco, Eduardo L.
AU - Cuzick, Jack
AU - Méndez-Hernández, Pablo
AU - Salmerón, Jorge
AU - Wheeler, Cosette
AU - Lazcano, Eduardo
AU - León, Leith
AU - Méndez, Pablo
AU - Hernández, Mauricio
AU - Wright, Thomas C.
AU - Moscicki, Anna Barbara
AU - Flores, Yvonne
AU - Stoler, Mark H.
AU - Carmona, Enrique
AU - Schmeler, Kathleen M.
AU - Bishai, David
AU - Hernández, Pilar
AU - Alvarez, Daniel
AU - Barrios, Elizabeth
AU - Mendiola, Indira
AU - González, Vicente
N1 - Funding Information:
This study was supported by the National Institute of Public Health of Mexico, the Coordinación de Investigación en Salud del Instituto Mexicano del Seguro Social, the Secretaría de Salud Tlaxcala, the Instituto Nacional de las Mujeres, and the Consejo Nacional de Ciencia y Tecnología [FOSISS 2013 202468]. Additional support has been provided by Roche Diagnostics, BD Diagnostics, DICIPA and Arbor Vita Corporation. The study sponsors did not played a role in designing the study, collecting, analyzing or interpreting the data, writing the report, or submitting this paper for publication. UC Berkeley Center for Global Public Health, Schoeneman Grant, Joint Medical Program Thesis Grant, and Cancer Research UK (C569/A10404).
Publisher Copyright:
© 2016 The Author(s).
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background: Cervical cancer remains an important cause of cancer mortality for Mexican women. HPV 16/18 typing may help to improve cervical cancer screening. Here we present the prevalence of high-risk human papillomavirus (hrHPV) including HPV16 and HPV18 from the FRIDA (Forwarding Research for Improved Detection and Access) population. Methods: Beginning in 2013, we recruited 30,829 women aged 30-64 in Tlaxcala, Mexico. Cervical samples were collected and tested for 14 hrHPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). We used logistic regression to estimate odds ratios with 95 % confidence intervals for hrHPV infections according to putative risk factors. Results: Prevalence of infection with any of the 14 hrHPV types was 11.0 %. The age-specific prevalence of all hrHPV formed a U-shaped curve with a higher prevalence for women aged 30-39 and 50-64 than women aged 40-49. Across all age groups, 2.0 % of women were positive for HPV16 and/or HPV18 (HPV16/18), respectively. HPV16/18 prevalence also showed a U-shaped curve with increased prevalence estimates for women aged both 30-39 and 60-64. Both prevalence curves had a significant quadratic age coefficient. Infections with hrHPV were positively associated with an increased number of lifetime sexual partners, a history of sexually transmitted disease, being unmarried, use of hormonal contraception, having a history of smoking and reported condom use in the multivariate model. Conclusions: The FRIDA population has a bimodal distribution of both hrHPV and HPV16/18 positivity with higher prevalences at ages 30-39 and 60-64. These findings will help to evaluate triage algorithms based on HPV genotyping. Trial registration: The trial is registered with ClinicalTrials.gov, number NCT02510027.
AB - Background: Cervical cancer remains an important cause of cancer mortality for Mexican women. HPV 16/18 typing may help to improve cervical cancer screening. Here we present the prevalence of high-risk human papillomavirus (hrHPV) including HPV16 and HPV18 from the FRIDA (Forwarding Research for Improved Detection and Access) population. Methods: Beginning in 2013, we recruited 30,829 women aged 30-64 in Tlaxcala, Mexico. Cervical samples were collected and tested for 14 hrHPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). We used logistic regression to estimate odds ratios with 95 % confidence intervals for hrHPV infections according to putative risk factors. Results: Prevalence of infection with any of the 14 hrHPV types was 11.0 %. The age-specific prevalence of all hrHPV formed a U-shaped curve with a higher prevalence for women aged 30-39 and 50-64 than women aged 40-49. Across all age groups, 2.0 % of women were positive for HPV16 and/or HPV18 (HPV16/18), respectively. HPV16/18 prevalence also showed a U-shaped curve with increased prevalence estimates for women aged both 30-39 and 60-64. Both prevalence curves had a significant quadratic age coefficient. Infections with hrHPV were positively associated with an increased number of lifetime sexual partners, a history of sexually transmitted disease, being unmarried, use of hormonal contraception, having a history of smoking and reported condom use in the multivariate model. Conclusions: The FRIDA population has a bimodal distribution of both hrHPV and HPV16/18 positivity with higher prevalences at ages 30-39 and 60-64. These findings will help to evaluate triage algorithms based on HPV genotyping. Trial registration: The trial is registered with ClinicalTrials.gov, number NCT02510027.
KW - HPV16/18
KW - Human papillomavirus DNA testing
KW - Mexico
KW - Prevalence
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=84984832903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84984832903&partnerID=8YFLogxK
U2 - 10.1186/s12879-016-1782-x
DO - 10.1186/s12879-016-1782-x
M3 - Article
C2 - 27585544
AN - SCOPUS:84984832903
SN - 1471-2334
VL - 16
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 461
ER -